Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Retension Pharmaceuticals Q3 2026 Results: Net Loss of $5.92M, Loss Widens

Retension Pharmaceuticals reported a significant increase in cash and cash equivalents to $9.2 million as of September 30, 2026, compared to $18.9 million at year-end 2025 (as restated), while total liabilities decreased from $6.7 million to $0.9 million. The company is preparing for a Phase 2b dose-ranging trial of its lead candidate RTN-001 in uncontrolled hypertension, with initial data expected in the first half of 2027.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-5.9-1.5
EPS (diluted, $ a share)$-7.33$-1.83

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: RTSN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Retension Pharmaceuticals, Inc.: key numbers

Share price
$11.46Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Retension Pharmaceuticals, Inc.

All →
8:10 AM ET 8-K
Financial Results

Retension Pharmaceuticals Financial Results

Retension Pharmaceuticals reported Q3 2026 financial results and provided a corporate update following its $51.75 million upsized IPO in October 2026. The company is currently conducting a Phase 2b clinical trial for its hypertension candidate RTN-001, with topline data expected in the first half of 2027.

Term
Q3 2026

“Completing our initial public offering was an important step for Retension, and it provides the capital to complete our Phase 2b clinical trial of RTN-001 and prepare for Phase 3.”

Eric Keller, Chief Executive Officer of Retension Pharmaceuticals
6:01 AM ET 8-K
Executive Compensation

Retension Pharmaceuticals Executive Compensation

Retension Pharmaceuticals appointed Robert Wong as Vice President and Chief Accounting Officer, effective November 2, 2026. His compensation package includes an annual base salary of $360,000, a 30% target bonus opportunity, a $20,000 sign-on bonus, and a stock option award for 25,000 shares.

Counterparty
Robert Wong
6:12 PM ET Form 4
Insider Buying

Retension Pharmaceuticals CEO Eric L. Keller Buys $250K of Stock

Eric L. Keller, CEO, bought 20,800 shares of Retension Pharmaceuticals, Inc. at $12.00 a share, worth $250K in total on Oct 13, 2026. Shares held after the trade: 423,377 (+5.2%).

Value
$250K
Shares
20,800
Price
$12.00
Role
CEO
Holding change
+5.2%
Trade date
Oct 13, 2026
6:11 PM ET Form 4
Insider Buying

Retension Pharmaceuticals Insider Franklin M. Berger Buys $120K of Stock

Franklin M. Berger bought 10,000 shares of Retension Pharmaceuticals, Inc. at $12.00 a share, worth $120K in total on Oct 13, 2026. Shares held after the trade: 10,000.

Value
$120K
Shares
10,000
Price
$12.00
Trade date
Oct 13, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.